Drug details

Belviq (lorcaserin hydrochloride)

type of

Belviq (lorcaserin hydrochloride) is a serotonin 2C receptor agonist indicated for the treatment of chronic weight management in adults with a body mass index (BMI) of 30 or greater (obese) as an addition to a reduced-calorie diet and exercise. Belviq is also approved for use by adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia).

This drug may have the following side effects:
  • nausea,
  • headache,
  • dizziness,
  • vomiting,
  • diarrhea,
  • cough,
  • runny or stuffy nose,
  • constipation,
  • dry mouth,
  • drowsiness,
  • sore throat, or
  • back pain,
  • muscle pain,
  • feeling tired,
  • fatigue,
  • urinary tract infection,
  • upper respiratory tract infection,
  • rash.
  • low blood sugar (hypoglycemia),
  • mental problems,
  • slow heartbeat,
  • painful erections,
The following drugs are related to Belviq, either as a replacement or used together:
  • Adipex-P (phentermine hydrochloride)
  • Alli (orlistat 60 mg)
  • Belviq XR (lorcaserin hydrochloride extended release tablets)
  • Didrex (benzphetamine)
  • Contrave (naltrexone hcl and bupropion hcl extended-release tablets)
  • Fastin (phentermine)
  • Saxenda (liraglutide [rdna origin]) injection)
  • Lomaira (phentermine hydrochloride tablets, usp)
  • Meridia (sibutramine hydrochloride monohydrate)
  • Xenical (orlistat 120 mg)
  • Qsymia (phentermine and topiramate)
  • Plenity (superabsorbent hydrogel particles in capsules)